Stability of emotional responding in schizophrenia

Behavior Therapy

Volumn 30, Issue 3, 1999, Pages 373-388

  Kring, Ann M ^a   Earnst, Kelly S ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; PERPHENAZINE; TIOTIXENE;

ADULT; AFFECT; AKINESIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EMOTION; EXPERIENCE; EXTRAPYRAMIDAL SYMPTOM; FACIAL EXPRESSION; HUMAN; INTERVIEW; MALE; SCHIZOIDISM; SCHIZOPHRENIA; SYMPTOM; TARDIVE DYSKINESIA;

EID: 0033505518     PISSN: 00057894     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0005-7894(99)80016-1     Document Type: Article

References (53)

1. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author.
2. Andreasen, N. C. (1982). Negative symptoms in schizophrenia: Definition and reliability. Archives of General Psychiatry, 39, 784-788.
3. Andreasen, N. C. (1983). The Scale for the Assessment of Negative Symptoms (SANS). Iowa City, IA: University of Iowa.
4. Berenbaum, H., & Oltmanns, T. F. (1992). Emotional experience and expression in schizophrenia and depression. Journal of Abnormal Psychology, 101, 37-44.
5. Blanchard, J. J., Mueser, K. T., & Bellack, A. S. (1998). Anhedonia, positive and negative affect, and social functioning in schizophrenia. Schizophrenia Bulletin, 24, 413-424.
6. Blanchard, J. J., & Neale, J. M. (1992). Medication effects: Conceptual and methodological issues in schizophrenia research. Clinical Psychology Review, 12, 345-361.
7. Carpenter, W. T., Jr., Heinrichs, D. W., & Alphs, L. D. (1985). Treatment of negative symptoms. Schizophrenia Bulletin, 11, 440-452.
8. Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.). Hillsdale, NJ: Erlbaum.
9. Cohen, J. (1992). A power primer. Psychological Bulletin, 112, 155-159.
10. Davison, P. S., Frith, C. D., Harrison-Read, P. E., & Johnstone, E. C. (1996). Facial and other non-verbal communicative behaviour in chronic schizophrenia. Psychological Medicine, 26, 707-713.
11. Delespaul, P. A. E. G. (1995). Assessing schizophrenia in daily life. Maastricht, The Netherlands: Universitaire Pers Maastricht.
12. deVries, M. W., Delespaul, P. A. E. G., Nicolson, N., & Bayer, H. (1993). Basic properties of illness and well-being. Phase I: Variable description foe the study of quality of life and clinical applications. Unpublished interim report to Solvay Duphar, IPSER Foundation.
13. DiMascio, A., Bernardo, D. L., Greenblatt, D. J., & Marder, J. E. (1976). A controlled trial of amantadine in drug-induced extrapyramidal disorders. Archives of General Psychiatry, 3, 599-602.
14. Dworkin, R. H., Clark, S. C., Amador, X. F., & Gorman, J. M. (1996). Does affective blunting in schizophrenia reflect affective deficit or neuromotor dysfunction? Schizophrenia Research, 20, 301-306.
15. Dworkin, R. H., Oster, H., Clark, S. C., & White, S. R. (1998). Affective expression and affective experience in schizophrenia. In M. F. Lenzenweger & R. H. Dworkin (Eds.), Origins and development of schizophrenia: Advances in experimental psychopathology (pp. 385-424). Washington, DC: American Psychological Association.
16. Earnst, K. S., Kring, A. M., Kadar, M. A., Salem, J. E., Shepard, D. A., & Loosen, P. T. (1996). Facial expression in schizophrenia. Biological Psychiatry, 40, 556-558.
17. Ekman, P. (1992). Facial expression and emotion. American Psychologist, 48, 384-392.
18. Faul, F., & Erdfelder, E. (1993). A priori-, post hoc-, and compromise power analyses for MS-DOS [Computer program]. Bonn, Germany: Bonn University.
19. First, M. B., Spitzer, R. L., Gibbon, M., & Williams, J. B. W. (1994). Structured Clinical Interview for Axis I DSM-IV Disorders - patient edition (SCID-I/P, version 2.0) [Computer software]. New York: Biometrics Research Department.
20. Gaebel, W., & Wolwer, W. (1992). Facial expression and emotional face recognition in schizophrenia and depression. European Archives of Psychiatry and Clinical Neuroscience, 242, 46-52.
21. Guy, W. (1976). ECDEU Assessment manual for psychopharmacology. [DHEW Pub. No. (ADM) 76-338.] Rockville, MD: National Institute of Mental Health.
22. Kane, J., Honigfeld, G., Singer, J., & Meltzer, H. (1988). Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789-796.
23. Krause, R., Steimer-Krause, E., & Hufnagel, H. (1992). Expression and experience of affects in paranoid schizophrenia. Revue Européenne de Psychologie Appliquée, 42, 131-138.
24. Krause, R., Steimer-Krause, E., Sanger-Alt, C., & Wagner, G. (1989). Facial expressions of schizophrenic patients and their interaction partners. Psychiatry, 52, 1-12.
25. Kring, A. M., Alpert, M., Neale, J. M., & Harvey, P. D. (1994). A multimethod, multichannel assessment of affective flattening in schizophrenia. Psychiatry Research, 54, 211-222.
26. Kring, A. M., Kerr, S. L., & Earnst, K. S. (1999). Schizophrenic patients show facial reactions to emotional facial expressions. Psychophysiology, 36, 1-7.
27. Kring, A. M., Kerr, S. L., Smith, D. A., & Neale, J. M. (1993). Flat affect in schizophrenia does not reflect diminished experience of emotion. Journal of Abnormal Psychology, 102, 507-517.
28. Kring, A. M., & Neale, J. M. (1996). Do schizophrenics show a disjunctive relationship among expressive, experiential, and psychophysiological components of emotion? Journal of Abnormal Psychology, 105, 249-257.
29. Kring, A. M., & Sloan, D. (1991). The facial expression coding system (FACES): A users guide. Unpublished coders manual.
30. Kring, A. M., Smith, D. A., & Neale, J. M. (1994). Individual differences in dispositional expressiveness: The development and validation of the emotional expressivity scale. Journal of Personality and Social Psychology, 66, 934-949.
31. Lang, P. J. (1995). The emotion probe: Studies of motivation and attention. American Psychologist, 50, 372-385.
32. Larsen, R. J., & Diener, E. (1992). Promises and problems with the circumplex model of emotion. Review of Personality and Social Psychology, 13, 25-59.
33. Levenson, R. W. (1994). Human emotion: A functional view. In P. Ekman & R. J. Davidson (Eds.), The nature of emotion: Fundamental questions. (pp. 123-126). New York: Oxford University Press.
34. Marder, S. R., Wirshing, W. C., & Van Putten, T. (1991). Drug treatment of schizophrenia: Overview of recent research. Schizophrenia Research, 4, 81-90.
35. Mattes, R. M., Schneider, F., Heimann, H., & Birbaumer, N. (1995). Reduced emotional response of schizophrenic patients in remission during social interaction. Schizophrenia Research, 17, 249-255.
36. Meltzer, H. Y. (1991). Pharmacologic treatment of negative symptoms. In J. F. Greden & R. Tandon (Eds.), Negative schizophrenic symptoms: Pathophysiology and clinical implications (pp. 217-231). Washington DC: American Psychiatric Press.
37. Miller, D. D., Perry, P. J., Cadoret, R. J., & Andreasen, N. C. (1994). Clozapine's effect on negative symptoms in treatment-refractory schizophrenics. Comprehensive Psychiatry, 35, 8-15.
38. Overall, J. E., & Gorham, D. R. (1988). The Brief Psychiatric Rating Scale (BPRS): Recent developments in ascertainment and scaling. Psychopharmacology Bulletin, 24, 97-99.
39. Pitman, R. K., Kolb, B., Orr, S. P., & Singh, M. M. (1987). Ethological study of facial behavior in nonparanoid and paranoid schizophrenic patients. American Journal of Psychiatry, 144, 99-102.
40. Presser, E. S., Csernansky, J. G., Kaplan, J., Thiemann, S., Becker, T. J., & Hollister, L. E. (1987). Depression, Parkinsonian symptoms, and negative symptoms in schizophrenics treated with neuroleptics. Journal of Nervous and Mental Disease, 175, 100-105.
41. Rifkin, A., Quitkin, F., & Klein, D. F. (1975). Akinesia: A poorly recognized drug-induced extrapyramidal behavioral disorder. Archives of General Psychiatry, 32, 672-674.
42. Russell, J. A. (1980). A circumplex model of affect. Journal of Personality and Social Psychology, 39, 1161-1178.
43. Scheffé, H. A. (1953). A method for judging all possible contrasts in the analysis of variance. Biometrika, 40, 87-104.
44. Schneider, F., Ellgring, H., Friedrich, J., Fus, I., Beyer, T., Hiemann, H., & Wimer, W. (1992). The effects of neuroleptics on facial action in schizophrenic patients. Pharmacopsychiatry, 25, 233-239.
45. Shrout, P. E., & Fleiss, J. L. (1979). Intraclass correlations: Uses in assessing rater reliability. Psychological Bulletin, 86, 420-428.
46. Sommers, A. A. (1985). Negative symptoms: Conceptual and methodological problems. Schizophrenia Bulletin, 11, 364-379.
47. Spohn, H. E., & Strauss, M. E. (1989). Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. Journal of Abnormal Psychology, 98, 367-380.
48. Thompson, P. A., Buckley, P. F., & Meltzer, H. Y. (1994). The brief psychiatric rating scale: Effect of scaling system on clinical assessment. Journal of Clinical Psychopharmacology, 14, 344-346.
49. Umbricht, D., & Kane, J. M. (1995). Risperidone: Efficacy and safety. Schizophrenia Bulletin, 21, 593-606.
50. Van Putten, T., & Marder, S. R. (1987). Behavioral toxicity of antipsychotic drugs. Journal of Clinical Psychiatry, 48(9, Suppl), 13-19.
51. Van Putten, T., May, P. R. A., & Wilkins, J. N. (1980). Importance of akinesia: Plasma chlorpromazine and prolactin levels. American Journal of Psychiatry, 137, 1446-1448.
52. Watson, D., Clark, L. A., & Tellegen, A. (1988). Development and validation of brief measures of positive and negative affect: The PANAS scales. Journal of Personality and Social Psychology, 54, 1063-1070.
53. Watson, D., & Tellegen, A. (1985). Toward a consensual structure of mood. Psychological Bulletin, 98, 219-235.